Visual storytelling for medical publications

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Addition of #elotuzumab to pomalidomide and dexamethasone led to one additional year of survival in patients with relapsed or refractory multiple #myeloma.
https://bit.ly/3QOFf8d
#VisualAbstract #in #hematology